UM study: Immunosuppressive drug associated with lower risk of death in COVID-19 patients
For the study, U-M researchers used data from 154 critically ill Michigan Medicine patients from early March to late April to formulate their conclusions. At the end of 28 days after patients were put on a ventilator, 36% of patients of non-tocilizumab and 18% of tocilizumab patients died. For patients still at the hospital at the end of the study, 82% of tocilizumab patients and 53% of non-tocilizumab patients stopped using a ventilator. However, just over half of the tocilizumab patients developed an additional infection but only 26% of non-tocilizumab patients did. It was only given to 25% of tocilizumab patients and 20% of non-tocilizumab patients.